Veterinary Dermatology Drugs Market

Executive Summary

Veterinary Dermatology Drugs Market was valued at US $8.38 billion in 2021 and is projected to grow at 10.29% CAGR over the forecast period to reach US $15.09 billion by 2027. Veterinary Dermatology Drugs Market represented US $1.49 billion opportunity over 2019-2021 and estimated to create US $6.70 billion opportunity in 2027 over 2021.

Veterinary Dermatology Drugs from Consainsights analyses the Veterinary Dermatology Drugs Market in the Life Sciences industry over the forecast period to 2027.

Veterinary Dermatology Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Veterinary Dermatology Drugs segmentation includes Animal, Route Of Administration, Indication, Distribution Channel and Geography.

Based on the Animal, the Veterinary Dermatology Drugs analysis covers Companion Animal, Livesstock Animal.

In Animal segment, Companion Animal segment has highest cagr growth of 9.10%.

Based on the Route Of Administration, the Veterinary Dermatology Drugs analysis covers Topical, Injectable, Oral.

In Route Of Administration segment, Topical segment has highest cagr growth of 9.10%.

Based on the Indication, the Veterinary Dermatology Drugs analysis covers Parasitic Infections, Allergic Infections, Others.

In Indication segment, Parasitic Infections segment has highest cagr growth of 9.10%.

Based on the Distribution Channel, the Veterinary Dermatology Drugs analysis covers Retail, Hospital Pharmacies, E-commerce.

In Distribution Channel segment, Retail segment has highest cagr growth of 9.10%.

Based on the region, the Veterinary Dermatology Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bayer AG, Bimeda, Inc., Merk & Co. Inc., Virbac, Ceva Sante Animale, Mars, Incorporated, Zoetis, Inc., Nestle S.A. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Animal

Introduction

In 2021, Livesstock Animal segment has the highest revenue of US $4.93 billion and is expected to grow at CAGR of 9.10% by 2027 Companion Animal segment has highest cagr growth of 9.10%.

Companion Animal

Companion Animal segment was valued at US $2.84 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $6.22 billion by 2027. Companion Animal segment represented US $0.61 billion opportunity over 2019-2021 and estimated to create US $2.76 billion opportunity in 2027 over 2021.

Livesstock Animal

Livesstock Animal segment was valued at US $4.05 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $8.87 billion by 2027. Livesstock Animal segment represented US $0.88 billion opportunity over 2019-2021 and estimated to create US $3.94 billion opportunity in 2027 over 2021.

Route Of Administration

Introduction

In 2021, Topical segment has the highest revenue of US $4.81 billion and is expected to grow at CAGR of 9.10% by 2027 Topical segment has highest cagr growth of 9.10%.

Topical

Topical segment was valued at US $3.95 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $8.66 billion by 2027. Topical segment represented US $0.86 billion opportunity over 2019-2021 and estimated to create US $3.85 billion opportunity in 2027 over 2021.

Injectable

Injectable segment was valued at US $1.25 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $2.73 billion by 2027. Injectable segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.21 billion opportunity in 2027 over 2021.

Oral

Oral segment was valued at US $1.69 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $3.69 billion by 2027. Oral segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.64 billion opportunity in 2027 over 2021.

Indication

Introduction

In 2021, Parasitic Infections segment has the highest revenue of US $5.37 billion and is expected to grow at CAGR of 9.10% by 2027 Parasitic Infections segment has highest cagr growth of 9.10%.

Parasitic Infections

Parasitic Infections segment was valued at US $4.41 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $9.66 billion by 2027. Parasitic Infections segment represented US $0.96 billion opportunity over 2019-2021 and estimated to create US $4.30 billion opportunity in 2027 over 2021.

Allergic Infections

Allergic Infections segment was valued at US $1.68 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $3.67 billion by 2027. Allergic Infections segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $1.63 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.80 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $1.75 billion by 2027. Others segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.78 billion opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Retail segment has the highest revenue of US $5.63 billion and is expected to grow at CAGR of 9.10% by 2027 Retail segment has highest cagr growth of 9.10%.

Retail

Retail segment was valued at US $4.63 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $10.14 billion by 2027. Retail segment represented US $1.00 billion opportunity over 2019-2021 and estimated to create US $4.50 billion opportunity in 2027 over 2021.

Hospital Pharmacies

Hospital Pharmacies segment was valued at US $1.45 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $3.17 billion by 2027. Hospital Pharmacies segment represented US $0.31 billion opportunity over 2019-2021 and estimated to create US $1.41 billion opportunity in 2027 over 2021.

E-commerce

E-commerce segment was valued at US $0.81 billion in 2019 and is projected to grow at 9.10% CAGR over the forecast period to reach US $1.78 billion by 2027. E-commerce segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.79 billion opportunity in 2027 over 2021.